SEC Form 4 · accession 0001005201-19-000023
Assertio Therapeutics, Inc · ASRT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Arthur J Higgins
Officer — Director, President and CEO · Director
Period of report
Feb 12, 2019
Accepted (ET)
Feb 14, 2019 · 4:21 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001005201
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF3,F1,F2 | — | Feb 12, 2019 | A | 292,237 | A | — | Feb 12, 2022 | Common Stock | 292,237 | 292,237 | D |
| Performance SharesF3,F4,F5 | — | Feb 12, 2019 | A | 38,064 | A | — | — | Common Stock | 38,064 | 38,064 | D |
Explanation of responses
- F1Each restricted stock unit represents a contingent right to receive one share of the registrant's common stock.
- F2One-third of these restricted stock units are scheduled to vest on each of February 12, 2020, 2021 and 2022, assuming continued employment through the applicable vesting date.
- F3The derivative securities were granted to the reporting person, and were not sold to the reporting person. As such, the reporting person did not pay any consideration for the derivative securities.
- F4Represents the current tranche of performance shares earned under the 2018 performance share award as of February 12, 2019, at which date the Compensation Committee certified the extent to which the current tranche performance criteria were achieved. Each earned performance share represents the contingent right to receive one share of common stock.
- F5Each performance share will convert into one share of common stock upon vesting and settlement in the first quarter of 2021.